rhBMP-2/CPM as an Adjuvant Therapy for Femur Fractures

ID Number 06-1239

Principal Investigator(s)
Edward C Yang

Department(s) or Division(s)


Recombinant human bone morphogenetic protein-2 (rhBMP-2) is an osteoinductive protein that directs uncommitted mesenchymal cells to differentiate into osteoblasts. The sequence of cellular events observed following injection of rhBMP-2 is similar to that observed in normal fracture repair and embryonic endochondral bone formation. The primary objective is to • To demonstrate the safety of administering rhBMP-2/CPM (either 1.0 mg/mL or 2.0 mg/mL) as an adjunct to internal fixation in subjects with fractures of the proximal femur. The key safety outcome is the incidence of secondary fracture displacement among subjects treated with rhBMP-2/CPM and those receiving standard surgical treatment (internal fixation) alone.

Contact Information
Veronica Emma
(718) 334-2663

Recruiting Patients: Yes